Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6HDKQ)

Drug Name
[3H]mibolerone Drug Info
Synonyms
Mibolerone; MIBOLERONE; 3704/9/4; Miboleronum; Mibolerona; Cheque; U-10,997; UNII-9OGY4BOR8D; NSC 72260; 9OGY4BOR8D; U 10997; Matenon; Miboleron; 17-beta-Hydroxy-7-alpha,17-dimethylestr-4-en-3-one; CHEBI:34849; U-10997; 17beta-Hydroxy-7alpha,17-dimethylestr-4-en-3-one; (7alpha,17beta)-17-hydroxy-7,17-dimethylestr-4-en-3-one; 7alpha-17alpha-dimethyl-19-nortestosterone; CDB 904; Cheque (Veterinary)
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
251636
ChEBI ID
CHEBI:34849
CAS Number
CAS 3704-09-4
TTD Drug ID
DM6HDKQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Androgen receptor (AR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [9]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [10]
Darolutamide DMV7YFT Prostate cancer 2C82.0 Approved [11]
Testosterone DM7HUNW Hot flushes GA30 Approved [12]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [13]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [14]
Fludrocortisone DMUDIR8 Addison disease 5A74.0 Approved [15]
ARN-509 DMT81LZ Acute myeloid leukaemia 2A60 Approved [16]
Nilutamide DMFN07X Prostate cancer 2C82.0 Approved [17]
Nandrolone DMFWKG1 Osteoporosis FB83.0 Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Androgen receptor messenger RNA (AR mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dihydrotestosterone DM3S8XC Prostate hyperplasia GA90 Phase 4 [3]
BAY 86-5044 DMRZLU4 Breast cancer 2C60-2C65 Phase 2 [19]
TRC-253 DMXI8CD Prostate cancer 2C82.0 Phase 1/2 [20]
IONIS-AR-2.5Rx DMF2DMS Prostate cancer 2C82.0 Phase 1/2 [21]
ISIS-AR DM8P3N5 Prostate cancer 2C82.0 Phase 1 [22]
EZN-4176 DMNPS59 Prostate cancer 2C82.0 Phase 1 [23]
EUGENOL DM7US1H Discovery agent N.A. Patented [24]
RU-58841 DMMEAZ2 Acne vulgaris ED80 Discontinued in Phase 1 [25]
flavone DMEQH6J Discovery agent N.A. Investigative [26]
APIGENIN DMI3491 Discovery agent N.A. Investigative [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prostate-specific antigen (KLK3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [27]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [28]
Selenium DM25CGV N. A. N. A. Approved [29]
Quercetin DM3NC4M Obesity 5B81 Approved [30]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [31]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [32]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [33]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [34]
Testosterone DM7HUNW Hot flushes GA30 Approved [35]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Matrilysin (MMP7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [37]
Quercetin DM3NC4M Obesity 5B81 Approved [38]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [39]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [40]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [41]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [42]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [43]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [44]
Clozapine DMFC71L Schizophrenia 6A20 Approved [45]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Kallikrein-2 (KLK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [30]
Testosterone DM7HUNW Hot flushes GA30 Approved [47]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [36]
Riluzole DMECBWN Amyotrophic lateral sclerosis 8B60.0 Approved [48]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [49]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [50]
Dutasteride DMQ4TJK Benign prostatic hyperplasia GA90 Approved [51]
Amphotericin B DMTAJQE Acne vulgaris ED80 Approved [52]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [53]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Homeobox protein Nkx-3.1 (NKX3-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [30]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [55]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [56]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [57]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [49]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [58]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [59]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [60]
Diethylstilbestrol DMN3UXQ Gonorrheal vaginitis GA02 Approved [61]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [62]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Acireductone dioxygenase (ADI1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [63]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [64]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [42]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [65]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [66]
Diethylstilbestrol DMN3UXQ Gonorrheal vaginitis GA02 Approved [61]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [50]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [67]
Dutasteride DMQ4TJK Benign prostatic hyperplasia GA90 Approved [35]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [68]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Inhibitor [2]
Androgen receptor messenger RNA (AR mRNA) TTKPW01 ANDR_HUMAN Agonist [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acireductone dioxygenase (ADI1) OT8IOD03 MTND_HUMAN Gene/Protein Processing [4]
Homeobox protein Nkx-3.1 (NKX3-1) OT0DO6ZU NKX31_HUMAN Gene/Protein Processing [5]
Kallikrein-2 (KLK2) OT9RE37R KLK2_HUMAN Gene/Protein Processing [6]
Matrilysin (MMP7) OTVT3SEJ MMP7_HUMAN Gene/Protein Processing [7]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Gene/Protein Processing [6]
Vascular endothelial growth factor A, long form OTIM9MZ3 VEGFA_HUMAN Gene/Protein Processing [8]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3456).
2 Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile... J Med Chem. 2000 Aug 24;43(17):3344-7.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
4 Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. Neoplasia. 2007 Aug;9(8):643-51. doi: 10.1593/neo.07415.
5 A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology. 1999 Nov;140(11):5451-4. doi: 10.1210/endo.140.11.7246.
6 Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999 Dec 1;59(23):5892-5.
7 Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J Biol Chem. 1996 Sep 27;271(39):23907-13. doi: 10.1074/jbc.271.39.23907.
8 Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells. Toxicology. 2015 Jul 3;333:45-52. doi: 10.1016/j.tox.2015.04.002. Epub 2015 Apr 3.
9 Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
10 Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
12 Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
13 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
14 Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
15 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
16 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
17 CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
18 Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
19 Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
20 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
21 Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. Expert Opin Pharmacother. 2019 Feb;20(2):163-172.
22 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
23 2011 Pipeline of Santaris Pharma.
24 Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2111-4.
25 Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4.
26 Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
27 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
28 Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. Clin Chim Acta. 2001 Oct;312(1-2):213-9. doi: 10.1016/s0009-8981(01)00626-x.
29 Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
30 Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
31 EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
32 Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate. 2007 Aug 1;67(11):1152-62. doi: 10.1002/pros.20585.
33 Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
34 An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003 Mar 24;88(6):822-7. doi: 10.1038/sj.bjc.6600817.
35 Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
36 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
37 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
38 Nobiletin, a citrus flavonoid, down-regulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells. Biosci Biotechnol Biochem. 2005 Feb;69(2):307-14. doi: 10.1271/bbb.69.307.
39 Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
40 Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
41 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
42 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
43 The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
44 Effect of mood stabilizers on gene expression in lymphoblastoid cells. J Neural Transm (Vienna). 2010 Feb;117(2):155-64.
45 Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology. 2007 Jun;121(2):266-75. doi: 10.1111/j.1365-2567.2007.02574.x. Epub 2007 Mar 7.
46 AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-B pathway. Environ Toxicol. 2016 Jul;31(7):866-76. doi: 10.1002/tox.22097. Epub 2014 Dec 24.
47 Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem. 2002 Dec 13;277(50):48366-71. doi: 10.1074/jbc.M209074200. Epub 2002 Oct 9.
48 Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells. Prostate. 2019 Feb;79(2):140-150. doi: 10.1002/pros.23719. Epub 2018 Oct 2.
49 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
50 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
51 Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
52 Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
53 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
54 Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007 Jan;6(1):51-60. doi: 10.1158/1535-7163.MCT-06-0144. Epub 2007 Jan 11.
55 Transcriptional regulation of the homeobox gene NKX3.1 by all-trans retinoic acid in prostate cancer cells. J Cell Biochem. 2006 Dec 1;99(5):1409-19. doi: 10.1002/jcb.21020.
56 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
57 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
58 Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.
59 Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP. Acta Pharmacol Sin. 2007 Mar;28(3):423-30. doi: 10.1111/j.1745-7254.2007.00501.x.
60 Effects of 9-cis retinoic acid on human homeobox gene NKX3.1 expression in prostate cancer cell line LNCaP. Asian J Androl. 2006 Jul;8(4):435-41. doi: 10.1111/j.1745-7262.2006.00171.x.
61 Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
62 A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostate cancer. Epigenetics. 2007 Apr-Jun;2(2):100-9.
63 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
64 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
65 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
66 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
67 Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
68 Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.